For research use only. Not for therapeutic Use.
MPI-0479605（Cat No.:I000979）is a potent and selective inhibitor of the mitotic kinase monopolar spindle 1 (Mps1/TTK), a critical regulator of the spindle assembly checkpoint during cell division. By inhibiting Mps1, MPI-0479605 disrupts the proper alignment of chromosomes, leading to cell cycle arrest and apoptosis, making it a valuable tool for studying mitotic processes and cancer research. Its selectivity and efficacy in inhibiting Mps1 make it an essential compound for researchers investigating cancer therapies that target mitotic kinases and cell division abnormalities.
| Catalog Number | I000979 |
| CAS Number | 1246529-32-7 |
| Molecular Formula | C₂₂H₂₉N₇O |
| Purity | ≥95% |
| Target | Mps1; Apoptosis |
| Solubility | DMSO: ≥ 11 mg/mL |
| Storage | Store at -20°C |
| IC50 | 1.8 nM |
| IUPAC Name | 6-N-cyclohexyl-2-N-(2-methyl-4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine |
| InChI | InChI=1S/C22H29N7O/c1-15-13-17(29-9-11-30-12-10-29)7-8-18(15)26-22-27-20-19(23-14-24-20)21(28-22)25-16-5-3-2-4-6-16/h7-8,13-14,16H,2-6,9-12H2,1H3,(H3,23,24,25,26,27,28) |
| InChIKey | OVJBNYKNHXJGSA-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CC(=C1)N2CCOCC2)NC3=NC4=C(C(=N3)NC5CCCCC5)NC=N4 |
| Reference | 1:Mol Cancer Ther. 2011 Dec;10(12):2267-75. doi: 10.1158/1535-7163.MCT-11-0453. Epub 2011 Oct 6. Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1.Tardif KD,Rogers A,Cassiano J,Roth BL,Cimbora DM,McKinnon R,Peterson A,Douce TB,Robinson R,Dorweiler I,Davis T,Hess MA,Ostanin K,Papac DI,Baichwal V,McAlexander I,Willardsen JA,Saunders M,Christophe H,Kumar DV,Wettstein DA,Carlson RO,Williams BL, PMID: 21980130 DOI: 10.1158/1535-7163.MCT-11-0453 </br><span>Abstract:</span> Mps1 is a dual specificity protein kinase that is essential for the bipolar attachment of chromosomes to the mitotic spindle and for maintaining the spindle assembly checkpoint until all chromosomes are properly attached. Mps1 is expressed at high levels during mitosis and is abundantly expressed in cancer cells. Disruption of Mps1 function induces aneuploidy and cell death. We report the identification of MPI-0479605, a potent and selective ATP competitive inhibitor of Mps1. Cells treated with MPI-0479605 undergo aberrant mitosis, resulting in aneuploidy and formation of micronuclei. In cells with wild-type p53, this promotes the induction of a postmitotic checkpoint characterized by the ATM- and RAD3-related-dependent activation of the p53-p21 pathway. In both wild-type and p53 mutant cells lines, there is a growth arrest and inhibition of DNA synthesis. Subsequently, cells undergo mitotic catastrophe and/or an apoptotic response. In xenograft models, MPI-0479605 inhibits tumor growth, suggesting that drugs targeting Mps1 may have utility as novel cancer therapeutics. |
